Rymedi, founded in 2017, operates at the intersection of Blockchain and Health Care, with a focus on enhancing patient and population healthcare data management. Positioned within the United States, this innovative software company aims to empower life sciences organizations to improve human health.
Rymedi offers blockchain-enabled solutions that support diagnostic and toxicology testing device companies, clinical trials, registries, and laboratory integrations. Their platform ensures secure storage of sensitive healthcare data, a vital feature in the increasingly digitized health and wellness sector.
Recently, Rymedi secured a $9.00M Series A investment, indicating robust market confidence in their model and potential for growth. The round, completed on 25 October 2023, attracted prominent investors such as Blockchange Ventures, White Star Capital, RW3 Ventures, Founderville.VC, and Blizzard Fund.
This financial backing underscores Rymedi's strategic position in leveraging blockchain technology to redefine healthcare data management.